What is the 13F Pro Quality Score for ELTX?

13F Pro ranks Elicio Therapeutics, Inc. (ELTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELTX's current score at https://13fpro.ai/company/ELTX (free sign-up required for the full ranking).

Where does 13F Pro source ELTX data?

All Elicio Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Elicio Therapeutics, Inc. files with the SEC under CIK 1601485. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELTX in?

Elicio Therapeutics, Inc. (ELTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELTX research updated on 13F Pro?

ELTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Elicio Therapeutics, Inc.(ELTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1601485 ELTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $28.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ELTX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Elicio Therapeutics, Inc. (ELTX), a Healthcare sector company. ELTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $28.3m in revenue and is scored on the micro-cap board instead. Top institutional holders of ELTX by reported 13-F value include Knoll Capital Management, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ELTX trades on the Nasdaq exchange and files with the SEC under CIK 1601485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elicio Therapeutics, Inc. directly from SEC EDGAR.

✦

Fun facts about Elicio Therapeutics, Inc.

Quirks, history, and lore behind ELTX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Boston, Massachusetts.
2
The Numbers
Like most clinical-stage biotechs, it runs on investor capital rather than product revenue, with a market cap in the tens of millions — the definition of high-risk, high-hope.
3
The History
Founded in the 2010s, it was built around a novel nanoparticle platform originally developed from academic research, aiming to reprogram the immune system rather than suppress it.
4
The Secret
Its core technology uses lymph-node-targeting nanoparticles to deliver antigens and immune signals, essentially teaching the body to tolerate or attack specific targets on command.
5
The Lore
Its lead programs take aim at cancer vaccines and autoimmune diseases — two of medicine's white whales — using the same underlying platform, which is either brilliantly flexible or very ambitious.
6
The Giveaway
Trading under the ticker ELTX, this Boston biotech's name literally combines "elicit" — as in, eliciting an immune response — with the suffix -io, the biotech naming gods' favorite syllable.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-8.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $2.3MFY23 —FY24 —FY25 —

Net Income

+23.8% YoY

$-39.6MFY 2025

FY22 $-28.2MFY23 $-35.2MFY24 $-51.9MFY25 $-39.6M

Operating Income

+16.2% YoY

$-37.7MFY 2025

FY22 $-23.7MFY23 $-35.7MFY24 $-45.0MFY25 $-37.7M

EPS (Diluted)

+39.3% YoY

$-2.58FY 2025

FY22 $-89.27FY23 $-6.96FY24 $-4.25FY25 $-2.58

Total Assets

-8.2% YoY

$25.9MFY 2025

FY22 $22.7MFY23 $27.1MFY24 $28.2MFY25 $25.9M

Total Debt

-50.1% YoY

$10.0MFY 2025

FY22 —FY23 —FY24 $20.0MFY25 $10.0M

Op. Cash Flow

+0.3% YoY

$-37.0MFY 2025

FY22 $-22.2MFY23 $-32.7MFY24 $-37.1MFY25 $-37.0M

Free Cash Flow

+0.5% YoY

$-37.0MFY 2025

FY22 $-22.8MFY23 $-32.8MFY24 $-37.2MFY25 $-37.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	$2.3M -91.9%	$28.3M +883.1%	$2.9M
Net Income	$-39.6M +23.8%	$-51.9M -47.5%	$-35.2M -24.8%	$-28.2M +48.3%	$-54.6M +31.9%	$-80.1M
Operating Income	$-37.7M +16.2%	$-45.0M -25.9%	$-35.7M -50.6%	$-23.7M +39.6%	$-39.3M +28.9%	$-55.3M
EPS (Diluted)	$-2.58 +39.3%	$-4.25 +38.9%	$-6.96 +92.2%	$-89.27 -4525.4%	$-1.93 +64.5%	$-5.43
Total Assets	$25.9M -8.2%	$28.2M +3.8%	$27.1M +19.8%	$22.7M -76.5%	$96.5M +103.8%	$47.3M
Total Debt	$10.0M -50.1%	$20.0M	—	—	$0.00 -100.0%	$635.0K
Operating Cash Flow	$-37.0M +0.3%	$-37.1M -13.4%	$-32.7M -47.4%	$-22.2M +57.9%	$-52.6M -130.0%	$-22.9M
Free Cash Flow	$-37.0M +0.5%	$-37.2M -13.4%	$-32.8M -43.5%	$-22.8M +56.9%	$-53.0M -131.3%	$-22.9M

Get alerted when ELTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Elicio Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELTX

Knoll Capital Management, LLC
$4.7M1,211,957 sh
BlackRock, Inc.
$3.0M766,005 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.2M572,151 sh
Caption Management, LLC
$1.6M418,100 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.2M311,354 sh
TORONTO DOMINION BANK
$782.0K200,000 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$709.3K181,400 sh
STATE STREET CORP
$701.5K179,420 sh
SIMPLEX TRADING, LLC
$687.0K175,700 sh
Caption Management, LLC
$647.9K165,700 sh

Fund	Value	Shares
Knoll Capital Management, LLC	$4.7M	1,211,957
BlackRock, Inc.	$3.0M	766,005
VANGUARD CAPITAL MANAGEMENT LLC	$2.2M	572,151
Caption Management, LLC	$1.6M	418,100
GEODE CAPITAL MANAGEMENT, LLC	$1.2M	311,354
TORONTO DOMINION BANK	$782.0K	200,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$709.3K	181,400
STATE STREET CORP	$701.5K	179,420
SIMPLEX TRADING, LLC	$687.0K	175,700
Caption Management, LLC	$647.9K	165,700

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELTX on your watchlist

Track score changes the day Elicio Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELTX a good stock to buy?

13F Pro's AI-powered analysis of Elicio Therapeutics, Inc. (ELTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELTX are available on the ELTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ELTX is classified as a small company.

Which hedge funds own ELTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Elicio Therapeutics, Inc.'s investment landscape.